First of all, we should understand that phase III clinical trial is the confirmation stage of treatment effect. Its purpose is to further verify the therapeutic effect and safety of drugs on patients with target indications, evaluate the relationship between benefits and risks, and finally provide sufficient basis for the evaluation of drug registration applications. Generally speaking, the trial should be a randomized blind controlled trial with sufficient sample size. This shows that the vaccine entering this stage has undergone a lot of experiments, which is helpful to obtain more abundant information on drug safety and effectiveness, evaluate the benefits/risks of drugs, and provide support for the product to be approved for marketing.
From the public news, we can know that the patent application for COVID-19 vaccine (Ad5-nCoV vaccine) jointly applied by Academician Chen Wei of the Institute of Military Medicine of the Academy of Military Sciences and Kangxinuo Bio has obtained the patent right, which is the first COVID-19 vaccine patent in China. This patent was applied on March 8, this year, and granted on August 8,1/kloc-0. The vaccine is one of the first phase I and phase II clinical trials in the world, which verifies the safety and immunogenicity of the vaccine. After the third phase of clinical trials, the vaccine can be mass-produced. ?
The COVID-19 epidemic has been prevalent all over the world for more than half a year, and many scientific research institutions at home and abroad have indicated that they should prepare for its long-term existence. Therefore, the research and development of vaccine has played an important role in the fight against epidemic in the world. After the vaccine with stable effect is produced, the risk of epidemic situation to us will be greatly reduced, and the use of vaccine also represents a big step closer to returning to normal production and life to a certain extent.